Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

25.83
+0.51002.01%
Pre-market: 26.000.1700+0.66%04:51 EDT
Volume:2.40M
Turnover:62.66M
Market Cap:2.54B
PE:-4.43
High:26.75
Open:25.76
Low:25.69
Close:25.32
52wk High:39.89
52wk Low:18.29
Shares:98.32M
Float Shares:94.49M
Volume Ratio:1.09
T/O Rate:2.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8279
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-24.22%
PB:-8.73
PE(LYR):-4.43

Loading ...

Binance flags 5 tokens as possible delisting risks

cryptonews
·
Aug 12

Ultragenyx Pharmaceutical: Will Grant Esjay a Non-Exclusive, Royalty-Free License to Market Its Generic Version of Dojolvi Beginning January 1, 2033

THOMSON REUTERS
·
Aug 11

Ultragenyx Pharmaceutical - Co and Bri Settle Dojolvi Patent Litigation with Esjay Pharma - SEC Filing

THOMSON REUTERS
·
Aug 11

Ultragenyx Settles Dojolvi Patent Suit, Grants Esjay Generic Entry from 2033

Reuters
·
Aug 11

UK's Mereo BioPharma Q2 Loss Narrows on Lower R&D Spending

Reuters
·
Aug 11

Binance to Delist Five Cryptocurrencies: Details

utoday
·
Aug 11

Ultragenyx Pharmaceutical (RARE) Gets a Buy from Evercore ISI

TIPRANKS
·
Aug 10

Ultragenyx Pharma Price Target Maintained with a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 10

How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) Q2 Revenue Gain And Narrower Net Loss

Simply Wall St.
·
Aug 10

Analysts Have Conflicting Sentiments on These Healthcare Companies: Stevanato Group (STVN), Ultragenyx Pharmaceutical (RARE) and PROCEPT BioRobotics (PRCT)

TIPRANKS
·
Aug 06

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Ultragenyx Pharmaceutical (RARE) and Beam Therapeutics (BEAM)

TIPRANKS
·
Aug 05

Ultragenyx price target raised to $81 from $79 at Canaccord

TIPRANKS
·
Aug 05

Ultragenyx Pharmaceutical Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Earnings Flash (RARE) Ultragenyx Pharmaceutical Posts Q2 Loss of $0.90 per Share, vs. FactSet Est $1.22 Loss

MT Newswires Live
·
Aug 05

Ultragenyx Q2 Revenue Rises 28% to Record High, Net Loss Narrows

Reuters
·
Aug 05

Ultragenyx Pharmaceutical Q2 EPS $(0.90) Beats $(1.51) Estimate, Sales $214.000M Beat $158.777M Estimate

Benzinga Earnings
·
Aug 05

Ultragenyx Q2 EPS USD -0.9

Reuters
·
Aug 05

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

GlobeNewswire
·
Aug 05

Ultragenyx EVP, Chief Legal Officer Karah Parschauer Disposes of 1,900 Common Shares for $47,348‬

Reuters
·
Aug 05

Ultragenyx Pharma is Maintained at Buy by Guggenheim

Dow Jones
·
Aug 04